17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle

17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

---

Glycolysis: Cytosolic Glucose Catabolism

Glycolysis is the ubiquitous, cytosolic ten-step metabolic pathway that oxidizes one mole of six-carbon glucose into two moles of three-carbon pyruvate, generating a net yield of 2 ATP (via substrate-level phosphorylation) and 2 NADH. Glycolysis operates in all human tissues and represents the obligate energy-generating pathway in cells lacking mitochondria (such as mature erythrocytes) or tissues functioning under hypoxic microenvironments (such as contracting ischemic skeletal muscle during ambulation).

                         Overview of Glycolytic Pathway
                         
                                  Glucose
                                     │
                       Hexokinase /  │  ATP ──> ADP
                       Glucokinase   │  (Step 1: Glucose Trapping)
                                     ▼
                             Glucose-6-Phosphate
                                     │
                         PFK-1       │  ATP ──> ADP
                    (Rate-Limiting)  │  Activated by AMP, F-2,6-BP
                                     │  Inhibited by ATP, Citrate
                                     ▼
                          Fructose-1,6-Bisphosphate
                                     │
                                     ▼ (Cleavage & Isomerization)
                     2 x Glyceraldehyde-3-Phosphate
                                     │
                                     │  2 NAD⁺ + 2 Pi ──> 2 NADH + 2 H⁺
                                     ▼
                        2 x 1,3-Bisphosphoglycerate
                                     │
                     PGK             │  2 ADP ──> 2 ATP
                    (Substrate-Level)│
                                     ▼
                         2 x 3-Phosphoglycerate
                                     │
                                     ▼
                       2 x Phosphoenolpyruvate (PEP)
                                     │
                     Pyruvate        │  2 ADP ──> 2 ATP
                     Kinase          │  (Substrate-Level Phosphorylation)
                                     ▼
                                2 x Pyruvate

Hexokinase vs. Glucokinase: The Isoenzyme Differential

The initial step of glycolysis involves the irreversible phosphorylation of glucose to glucose-6-phosphate (G-6-P) by transferring a phosphate from ATP, trapping glucose intracellularly (GLUT transporters cannot transport phosphorylated hexoses). This reaction is catalyzed by two distinct isoenzymes exhibiting profound kinetic and regulatory differences:

1. Hexokinase (Isoforms I–III):
   • Tissue Distribution: Ubiquitously expressed in virtually all peripheral tissues, including the brain, skeletal muscle, peripheral nerves, and plantar cutaneous tissues.
   • Kinetic Properties: Exhibits a very low $K_m$ (~0.05 mM; high affinity for glucose) and a low $V_{\max}$.
   • Physiological Role: Because normal fasting blood glucose is ~5 mM, hexokinase operates at near-maximal velocity even during starvation or hypoglycemia, guaranteeing that essential peripheral tissues can continuously extract basal glucose from circulating blood. The low $V_{\max}$ prevents peripheral cells from hoarding and trapping excess glucose beyond their metabolic capacity.
   • Allosteric Regulation: Potently inhibited by its reaction product, Glucose-6-Phosphate (G-6-P) (feedback product inhibition).
2. Glucokinase (Hexokinase IV):
   • Tissue Distribution: Expressed exclusively in liver parenchymal hepatocytes and pancreatic $\beta$-islet cells.
   • Kinetic Properties: Exhibits a very high $K_m$ (~10 mM; low affinity for glucose) and a high $V_{\max}$ with sigmoidal cooperative kinetics.
   • Physiological Role: In the postprandial state, portal vein blood glucose surges. Glucokinase becomes active only when glucose levels rise, rapidly phosphorylating vast quantities of glucose to direct it toward hepatic glycogen synthesis and lipogenesis. Glucokinase functions as the primary glucose sensor in pancreatic $\beta$-cells, governing insulin secretion thresholds.
   • Regulation: NOT inhibited by G-6-P. Instead, it is inhibited by Fructose-6-phosphate via binding to Glucokinase Regulatory Protein (GKRP), which sequesters glucokinase reversibly inside the hepatocyte nucleus. High cytosolic glucose triggers dissociation from GKRP and translocation back into the cytoplasm. Glucokinase expression is transcriptionally induced by insulin.
   • Clinical Board Correlation: Heterozygous inactivating loss-of-function mutations in the glucokinase gene (GCK) impair pancreatic glucose sensing, producing Maturity-Onset Diabetes of the Young Type 2 (MODY 2), characterized by non-progressive, mild fasting hyperglycemia that typically does not require pharmacological therapy.

Rate-Limiting Step: Phosphofructokinase-1 (PFK-1)

The phosphorylation of Fructose-6-Phosphate to Fructose-1,6-Bisphosphate (F-1,6-BP) catalyzed by Phosphofructokinase-1 (PFK-1) is the committed, irreversible, and rate-limiting step of glycolysis:

• Allosteric Inhibitors: Elevated intracellular ATP and Citrate (from the TCA cycle) signal that cellular energy stores are abundant. Both bind allosteric sites on PFK-1, stabilizing the low-affinity T-state and depressing glycolytic flux.
• Allosteric Activators: High AMP (a sensitive indicator of energy depletion) and Fructose-2,6-Bisphosphate (F-2,6-BP) potently override ATP inhibition, stabilizing the high-affinity R-state and accelerating glycolysis.

The Tandem Bifunctional PFK-2 / FBPase-2 Enzyme

Fructose-2,6-bisphosphate is not an intermediate of glycolysis; it is purely a potent allosteric regulatory molecule. Its steady-state intracellular concentration is governed by a unique bifunctional enzyme containing two opposing catalytic domains on a single polypeptide chain: 6-Phosphofructo-2-Kinase (PFK-2) and Fructose-2,6-Bisphosphatase (FBPase-2):

              Hormonal Regulation of the Bifunctional PFK-2 / FBPase-2 Switch

      FED STATE (High Insulin / Low Glucagon)       FASTING STATE (High Glucagon / Low Insulin)
      ───────────────────────────────────────       ───────────────────────────────────────────
      - Insulin activates Protein Phosphatase        - Glucagon elevates cAMP ──> activates PKA
      - DEPHOSPHORYLATION of Bifunctional Enzyme     - PHOSPHORYLATION of Bifunctional Enzyme
      - PFK-2 ACTIVE / FBPase-2 INACTIVE             - FBPase-2 ACTIVE / PFK-2 INACTIVE
      - [Fructose-2,6-Bisphosphate] RISES            - [Fructose-2,6-Bisphosphate] FALLS
      - PFK-1 ACTIVATED                              - PFK-1 INHIBITED / FBPase-1 ACTIVATED
      - GLYCOLYSIS ACCELERATES                       - GLUCONEOGENESIS ACCELERATES

• Fed State (Insulin Dominant): Insulin activates protein phosphatases, which dephosphorylate the bifunctional enzyme. Dephosphorylation activates the PFK-2 domain and inactivates the FBPase-2 domain. F-2,6-BP levels surge, strongly stimulating PFK-1 to drive glycolysis.
• Fasting State (Glucagon Dominant): Glucagon binds hepatic $G_s$-coupled receptors, elevating cAMP and activating Protein Kinase A (PKA). PKA phosphorylates the bifunctional enzyme, inactivating PFK-2 and activating FBPase-2. F-2,6-BP is degraded back to fructose-6-P, halting PFK-1 activity and relieving inhibition on fructose-1,6-bisphosphatase-1 to stimulate gluconeogenesis.

Pyruvate Kinase & Hemolytic Anemia

Pyruvate Kinase catalyzes the final irreversible step of glycolysis: converting phosphoenolpyruvate (PEP) to pyruvate while transferring a high-energy phosphate to ADP, yielding 1 ATP via substrate-level phosphorylation:

• Regulation: Allosterically activated by Fructose-1,6-bisphosphate (feedforward activation); inhibited by ATP and alanine. In the liver, it is phosphorylated and inactivated by PKA in response to glucagon.
• Pyruvate Kinase Deficiency: Autosomal recessive enzymatic deficiency; represents the second most frequent cause of hereditary non-spherocytic hemolytic anemia (surpassed only by G6PD deficiency). Because mature erythrocytes possess no mitochondria, they rely 100% on glycolysis for ATP generation. Depleted ATP disables the active $Na^+/K^+$ ATPase and $Ca^{2+}$ pumps, leading to intracellular potassium/water loss, cellular dehydration, membrane rigidification (echinocytes / burr cells), and splenic macrophage destruction (extravascular hemolysis).
  • Compensatory Board Pearl: Due to the glycolytic block at the terminal step, upstream glycolytic intermediates accumulate, notably 2,3-Bisphosphoglycerate (2,3-BPG). Elevated 2,3-BPG binds deoxyhemoglobin, shifting the oxygen-hemoglobin dissociation curve to the right, thereby enhancing oxygen delivery to ischemic peripheral tissues and mitigating clinical anemia symptoms.

Anaerobic Glycolysis: Lactate Dehydrogenase (LDH)

Under anaerobic conditions (such as severely ischemic diabetic foot ulcers, hypoperfused peripheral tissues in septic shock, or intensely exercising skeletal muscle), the mitochondrial electron transport chain cannot reoxidize NADH back to $NAD^+$. Without $NAD^+$, the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) halts, shutting down all ATP generation. To prevent metabolic arrest, cytosolic Lactate Dehydrogenase (LDH) reduces pyruvate into lactate, simultaneously oxidizing NADH to $NAD^+$: $\text{Pyruvate} + \text{NADH} + H^+ \rightleftharpoons \text{Lactate} + \text{NAD}^+$ Lactate diffuses out of ischemic muscle and erythrocytes into the bloodstream, where it travels to the liver to be reconverted to glucose via gluconeogenesis (The Cori Cycle).

---

The Pyruvate Dehydrogenase Complex (PDC)

In the presence of adequate oxygen, pyruvate generated by cytosolic glycolysis is transported across the inner mitochondrial membrane into the mitochondrial matrix by the mitochondrial pyruvate carrier (MPC). Within the matrix, pyruvate undergoes irreversible oxidative decarboxylation to enter the citric acid cycle:

$\text{Pyruvate} + \text{NAD}^+ + \text{CoA} \xrightarrow{\text{PDC}} \text{Acetyl-CoA} + \text{CO}_2 + \text{NADH} + H^+$

                  Architecture of the Pyruvate Dehydrogenase Complex
                  
                       Pyruvate ───> CO2
                           │
               [E1: Pyruvate Dehydrogenase]  <─── Requires TPP (Vitamin B1)
                           │
                           ▼ Hydroxyethyl-TPP
               [E2: Dihydrolipoyl Transacetylase] <─── Requires Lipoic Acid & CoA (B5)
                           │                          (Inhibited by Arsenic)
                           ▼ Acetyl-CoA
               [E3: Dihydrolipoyl Dehydrogenase] <─── Requires FAD (B2) & NAD⁺ (B3)
                           │
                        NADH + H⁺

The Three Subunits & Five Essential Cofactors

The PDC is a massive multi-enzyme complex composed of three catalytic subunits ($E_1, E_2, E_3$) functioning in strict sequential coordination, requiring five essential coenzymes (Mnemonic: "Tender Loving Care For Nancy"):

1. $E_1$ (Pyruvate Dehydrogenase): Requires Thiamine Pyrophosphate (TPP, Vitamin $B_1$) to decarboxylate pyruvate, releasing $CO_2$ and generating a hydroxyethyl-TPP intermediate.
2. $E_2$ (Dihydrolipoyl Transacetylase): Requires Lipoic Acid and Coenzyme A (CoA, Vitamin $B_5$ / pantothenic acid) to accept the acetyl group and transfer it to CoA, generating high-energy Acetyl-CoA.
3. $E_3$ (Dihydrolipoyl Dehydrogenase): Requires Flavin Adenine Dinucleotide (FAD, Vitamin $B_2$ / riboflavin) and Nicotinamide Adenine Dinucleotide ($NAD^+$, Vitamin $B_3$ / niacin) to reoxidize the reduced dihydrolipoamide back to active lipoic acid, transferring electrons to $NAD^+$ to yield NADH.

Regulation & Clinical Pathology of PDC

• Covalent Phosphorylation: Regulated by PDC Kinase and PDC Phosphatase:
  • PDC Kinase phosphorylates and inactivates $E_1$. The kinase is activated by high energy markers: Acetyl-CoA, ATP, and NADH.
  • PDC Phosphatase dephosphorylates and activates $E_1$. The phosphatase is stimulated by $Ca^{2+}$ (elevated during skeletal muscle contraction) and insulin.
• Arsenic Poisoning: Trivalent arsenic (arsenite) binds covalently to the vicinal sulfhydryl groups of lipoic acid, completely inactivating $E_2$ of PDC (as well as $\alpha$-ketoglutarate dehydrogenase). This halts mitochondrial respiration, presenting with vomiting, rice-water diarrhea, garlic-scented breath, QT prolongation, and hyperkeratotic skin changes on the palms and soles with Mees lines on the nails.
• Thiamine ($B_1$) Deficiency (Wernicke-Korsakoff / Beriberi): Impairs $E_1$, preventing pyruvate from entering the TCA cycle. Pyruvate is forced into lactate, causing severe lactic acidosis. Administering intravenous glucose to an alcoholic patient before thiamine supplementation precipitates acute Wernicke encephalopathy (ataxia, confusion, ophthalmoplegia).

---

The Tricarboxylic Acid (TCA) Cycle

The Tricarboxylic Acid (TCA, Krebs, or Citric Acid) cycle is the central amphibolic hub of aerobic metabolism situated entirely within the mitochondrial matrix. It oxidizes acetyl groups derived from carbohydrate, fatty acid, and amino acid catabolism, capturing high-energy electrons to power ATP synthesis via oxidative phosphorylation:

                              The Tricarboxylic Acid (TCA) Cycle
                              
                                   Acetyl-CoA (2C) + Oxaloacetate (4C)
                                                  │
                                                  ▼ (Citrate Synthase)
                                             Citrate (6C)
                                                  │
                                                  ▼ (Aconitase)
                                            Isocitrate (6C)
                                                  │
                    Isocitrate Dehydrogenase      │  NAD⁺ ──> NADH + CO2
                        (Rate-Limiting)           │  Activated by ADP
                                                  ▼  Inhibited by ATP, NADH
                                        alpha-Ketoglutarate (5C)
                                                  │
                    alpha-KGDH Complex            │  NAD⁺ + CoA ──> NADH + CO2
                    (Requires 5 Cofactors)        │  (Same 5 cofactors as PDC!)
                                                  ▼
                                           Succinyl-CoA (4C)
                                                  │
                    Succinyl-CoA Synthetase       │  GDP + Pi ──> GTP
                    (Substrate-Level)             ▼
                                            Succinate (4C)
                                                  │
                    Succinate Dehydrogenase       │  FAD ──> FADH2
                    (Complex II in ETC!)          ▼
                                             Fumarate (4C)
                                                  │
                                                  ▼ (Fumarase)
                                              Malate (4C)
                                                  │
                    Malate Dehydrogenase          │  NAD⁺ ──> NADH
                                                  ▼
                                           Oxaloacetate (4C)

Key Enzymatic Steps & Stoichiometry

1. Citrate Synthase: Condenses Oxaloacetate (4C) and Acetyl-CoA (2C) to form Citrate (6C), releasing CoA.
2. Isocitrate Dehydrogenase: Catalyzes the oxidative decarboxylation of isocitrate to $\alpha$-ketoglutarate, yielding 1 NADH and 1 $CO_2$. This represents the rate-limiting, pace-maker step of the TCA cycle. Strongly activated by ADP; inhibited by ATP and NADH.
3. $\alpha$-Ketoglutarate Dehydrogenase Complex: Catalyzes the oxidative decarboxylation of $\alpha$-ketoglutarate to Succinyl-CoA, releasing 1 NADH and 1 $CO_2$. Crucially, this multienzyme complex requires the identical five cofactors as the Pyruvate Dehydrogenase Complex (TPP, lipoic acid, CoA, FAD, $NAD^+$) and is equally vulnerable to arsenic toxicity.
4. Succinyl-CoA Synthetase (Succinate Thiokinase): Cleaves the high-energy thioester bond of succinyl-CoA to yield succinate and 1 GTP via substrate-level phosphorylation (GTP readily transfers its terminal phosphate to ADP via nucleoside diphosphate kinase to generate 1 ATP).
5. Succinate Dehydrogenase: Oxidizes succinate to fumarate, reducing FAD to $FADH_2$. This enzyme is physically embedded directly within the inner mitochondrial membrane, where it functions concurrently as Complex II of the Electron Transport Chain.
6. Malate Dehydrogenase: Oxidizes malate back to oxaloacetate, producing 1 NADH to complete the cyclic pathway.

Net Stoichiometric Yield per Turn (Per 1 Mole of Acetyl-CoA):

• 3 NADH (via isocitrate DH, $\alpha$-ketoglutarate DH, malate DH)
• 1 $FADH_2$ (via succinate DH)
• 1 GTP (= 1 ATP via substrate-level phosphorylation)
• 2 $CO_2$ (fully oxidized carbon waste) (Note: Because 1 glucose yields 2 acetyl-CoA molecules, double these figures per glucose molecule: 6 NADH, 2 $FADH_2$, 2 GTP, and 4 $CO_2$).

---

Gluconeogenesis: Biosynthesis of Endogenous Glucose

Gluconeogenesis is the metabolic pathway that synthesizes glucose from non-carbohydrate carbon substrates during periods of fasting ($>12-18$ hours) or intense exercise. Gluconeogenesis occurs predominantly in the liver (~90%) and to a lesser extent in the renal cortex (~10%). Skeletal muscle cannot perform gluconeogenesis because it lacks glucose-6-phosphatase.

Gluconeogenic Substrates

1. Lactate: Released by anaerobic glycolysis in erythrocytes and exercising skeletal muscle; converted to pyruvate in the liver via LDH (Cori cycle).
2. Glucogenic Amino Acids: Chiefly Alanine, released by muscle proteolysis; converted to pyruvate via alanine aminotransferase (ALT) (Cahill cycle).
3. Glycerol: Released from adipose tissue lipolysis of triglycerides; phosphorylated by hepatic glycerol kinase to glycerol-3-phosphate and oxidized to dihydroxyacetone phosphate (DHAP).
4. Propionyl-CoA: Derived from the oxidation of odd-chain fatty acids and branched-chain amino acids; converted to methylmalonyl-CoA and succinyl-CoA to enter the TCA cycle. (Critical Rule: Even-chain fatty acids CANNOT yield net glucose because the pyruvate dehydrogenase reaction is completely irreversible, and the two carbons entering as acetyl-CoA are lost as two molecules of $CO_2$ before oxaloacetate is regenerated).

The Four Irreversible Bypass Enzymes

Gluconeogenesis reverses glycolysis but must circumvent the three thermodynamically irreversible glycolytic reactions (hexokinase, PFK-1, and pyruvate kinase) utilizing four specialized bypass enzymes:

                   The Four Bypass Reactions of Gluconeogenesis

    GLYCOLYSIS (Irreversible Steps)              GLUCONEOGENESIS (Bypass Enzymes)
    ───────────────────────────────              ────────────────────────────────
    1. Glucose ──> Glucose-6-P                   4. GLUCOSE-6-PHOSPHATASE
       (Hexokinase / Glucokinase)                   (Located in ER Lumen of Liver/Kidney)
                                                    Glucose-6-P ──> Free Glucose + Pi
                                                 ────────────────────────────────
    2. Fructose-6-P ──> Fructose-1,6-BP          3. FRUCTOSE-1,6-BISPHOSPHATASE-1
       (PFK-1: Rate-Limiting Glycolysis)            (RATE-LIMITING OF GLUCONEOGENESIS)
                                                    F-1,6-BP ──> Fructose-6-P + Pi
                                                    Inhibited by AMP & F-2,6-BP
                                                 ────────────────────────────────
    3. Phosphoenolpyruvate ──> Pyruvate          2. PEPCK (Cytosol/Mitochondria)
       (Pyruvate Kinase)                            Oxaloacetate + GTP ──> PEP + CO2 + GDP
                                                 1. PYRUVATE CARBOXYLASE (Mitochondria)
                                                    Pyruvate + CO2 + ATP ──> Oxaloacetate
                                                    Requires BIOTIN (B7); Activated by Acetyl-CoA

1. Bypass Step 1: Pyruvate Carboxylase:
   • Located strictly within the mitochondrial matrix.
   • Converts Pyruvate + $CO_2 + \text{ATP} \longrightarrow \text{Oxaloacetate} + \text{ADP} + P_i$.
   • Cofactor: Requires Biotin (Vitamin $B_7$) to transfer activated $CO_2$.
   • Allosteric Activator: Obligately and allosterically activated by Acetyl-CoA (derived from fatty acid $\beta$-oxidation). High acetyl-CoA signals that energy is plentiful, automatically redirecting pyruvate into gluconeogenesis rather than the TCA cycle.
   • The Malate Shuttle: Oxaloacetate cannot cross the inner mitochondrial membrane. It is reduced to malate, traverses the membrane via the malate-aspartate shuttle, and is reoxidized back to oxaloacetate in the cytosol.
2. Bypass Step 2: Phosphoenolpyruvate Carboxykinase (PEPCK):
   • Located in the cytosol and mitochondria.
   • Converts $\text{Oxaloacetate} + \text{GTP} \longrightarrow \text{Phosphoenolpyruvate (PEP)} + \text{GDP} + \text{CO}_2$.
   • Transcriptionally induced by glucagon and cortisol; repressed by insulin.
3. Bypass Step 3: Fructose-1,6-Bisphosphatase-1 (FBPase-1):
   • Cytosolic enzyme catalyzing: $\text{Fructose-1,6-Bisphosphate} + H_2O \longrightarrow \text{Fructose-6-Phosphate} + P_i$.
   • This is the committed, rate-limiting step of gluconeogenesis.
   • Regulation: Allosterically inhibited by AMP and Fructose-2,6-Bisphosphate (F-2,6-BP). Activated by ATP and citrate.
4. Bypass Step 4: Glucose-6-Phosphatase:
   • Embedded in the membrane of the endoplasmic reticulum (ER), with its active catalytic site facing the ER lumen. Expressed exclusively in the liver and renal cortex (entirely absent in skeletal muscle).
   • Cleaves the phosphate to release free, unphosphorylated glucose, which is transported into the blood via GLUT2 to maintain systemic normoglycemia.

---

Glycogen Metabolism: Synthesis & Degradation

Glycogen is a highly branched, multimeric polymer of $\alpha$-D-glucose functioning as the primary rapidly mobilizable carbohydrate storage reserve. It is stored primarily in hepatocytes (buffering systemic blood glucose during fasting) and skeletal muscle fibers (providing immediate autonomous ATP during anaerobic contraction).

• Polymer Architecture: Glucose residues in linear chains are linked by $\alpha$-1,4-glycosidic bonds. Branch points occur approximately every 8 to 12 residues, linked by $\alpha$-1,6-glycosidic bonds.

                        Glycogen Synthesis & Degradation Pathways

              GLYCOGENESIS (Synthesis)                    GLYCOGENOLYSIS (Breakdown)
              ────────────────────────                    ──────────────────────────
              Glucose-6-Phosphate                         GLYCOGEN POLYMER
                     │                                           │
                     ▼ (Phosphoglucomutase)                      ▼ (Glycogen Phosphorylase + PLP)
              Glucose-1-Phosphate                         Glucose-1-Phosphate (90%)
                     │                                           │ (Cleaves alpha-1,4 bonds)
                     ▼ (UDP-Glucose Pyrophosphorylase)           ▼
              UDP-Glucose                                 Limit Dextrin (4 residues before branch)
                     │                                           │
                     ▼ (GLYCOGEN SYNTHASE: Rate-Limiting)        ▼ (DEBRANCHING ENZYME)
              Elongated alpha-1,4 chains                  1. 4-alpha-Glucanotransferase (moves 3 glucoses)
                     │                                    2. alpha-1,6-Glucosidase (cleaves branch point)
                     ▼ (BRANCHING ENZYME)                        │
              alpha-1,6 Branch Points                            ▼
              GLYCOGEN POLYMER                            FREE GLUCOSE (10%)

Glycogenesis (Glycogen Synthesis)

1. Glucose is converted to Glucose-6-P $\rightarrow$ Glucose-1-P $\rightarrow$ UDP-Glucose (via UDP-glucose pyrophosphorylase).
2. Glycogen Synthase (Rate-Limiting Step): Transfers glucose from UDP-glucose to a growing glycogen chain, forming $\alpha$-1,4-glycosidic bonds. Activated by dephosphorylation (induced by insulin) and allosterically by Glucose-6-Phosphate. Inactivated by PKA-mediated phosphorylation (glucagon and epinephrine).
3. Branching Enzyme (Amylo-$\alpha$(1,4 $\rightarrow$ 1,6)-transglycosylase): Cleaves an oligomer of ~7 residues from a chain and transfers it to a more interior residue, creating an $\alpha$-1,6-glycosidic branch. Branching dramatically increases polymer solubility and creates numerous non-reducing ends for rapid degradation.

Glycogenolysis (Glycogen Breakdown)

1. Glycogen Phosphorylase (Rate-Limiting Step): Cleaves $\alpha$-1,4 bonds sequentially from non-reducing ends via phosphorolysis, yielding Glucose-1-Phosphate (G-1-P). It requires Pyridoxal Phosphate (PLP, Vitamin $B_6$) as an essential catalytic cofactor. Phosphorylase halts when 4 glucose residues remain before an $\alpha$-1,6 branch point (termed a limit dextrin):
   • Regulation: Phosphorylated and activated by Phosphorylase Kinase (activated by PKA in response to glucagon in liver and epinephrine in liver and muscle). In exercising muscle, high AMP allosterically activates unphosphorylated phosphorylase directly, while $Ca^{2+}$ released from the sarcoplasmic reticulum binds calmodulin to activate phosphorylase kinase.
2. Debranching Enzyme (Bifunctional):
   • 4-$\alpha$-D-Glucanotransferase: Cleaves the outer 3 of the 4 remaining glucosyl residues from the limit branch and transfers them to the end of a neighboring linear chain, extending the $\alpha$-1,4 sequence for phosphorylase.
   • $\alpha$-1,6-Glucosidase: Hydrolytically cleaves the single remaining glucose residue at the branch point, releasing 1 molecule of FREE, unphosphorylated GLUCOSE.
   • Stoichiometric Ratio: Glycogenolysis yields approximately 90% Glucose-1-Phosphate (cleaved by phosphorylase) and 10% Free Glucose (cleaved by $\alpha$-1,6-glucosidase).

---

Glycogen Storage Diseases (GSDs)

Inherited defects in specific enzymes of glycogen synthesis or degradation produce abnormal glycogen accumulation in tissue compartments, categorized as Glycogen Storage Diseases (all autosomal recessive):

                  Glycogen Storage Diseases: Clinical Classification

     TYPE I: VON GIERKE                     TYPE II: POMPE
     - Glucose-6-Phosphatase defect         - Lysosomal Acid Maltase defect
     - Severe fasting hypoglycemia          - Accumulates in LYSOSOMES
     - Massive hepatomegaly                 - Massive CARDIOMEGALY, HF
     - Lactic acidosis, Hyperuricemia       - Early infantile death
     - Normal glycogen structure            - "Pompe trashes the PUMP"
     ─────────────────────────────────────────────────────────────────
     TYPE III: CORI                         TYPE V: McARDLE
     - Debranching Enzyme defect            - Muscle Phosphorylase defect
     - Short outer branches (LIMIT DEXTRIN) - Painful muscle cramps in exercise
     - Mild hypoglycemia, Hepatomegaly      - Exercise-induced MYOGLOBINURIA
     - Normal blood lactate                 - Normal blood glucose
     - Gluconeogenesis intact!              - "SECOND WIND" phenomenon

Type I: Von Gierke Disease (Glucose-6-Phosphatase Deficiency)

• Enzyme Defect: Deficiency of Glucose-6-Phosphatase (Type Ia) or the G-6-P translocase (Type Ib) in the endoplasmic reticulum of the liver and kidneys.
• Pathophysiology: Blocks the final common step of both glycogenolysis and gluconeogenesis. Free glucose cannot be exported into the blood. Trapped G-6-P shunts into glycolysis, producing massive pyruvate, lactate, and acetyl-CoA, while activating HMP shunt and lipid synthesis.
• Clinical Presentation:
  • Severe, life-threatening fasting hypoglycemia within 2-4 hours of feeding.
  • Massive hepatomegaly and renomegaly with soft abdominal distension (due to excessive normal-structure glycogen storage).
  • Lactic Acidosis: Excess pyruvate is converted to lactate, competing with uric acid for renal tubular excretion.
  • Hyperuricemia & Severe Clinical Gout: Decreased renal uric acid clearance combined with accelerated purine synthesis leads to acute gouty arthritis, frequently presenting in the first metatarsophalangeal joint (podagra) in adolescents and young adults.
  • Hyperlipidemia: Elevated triglycerides and cholesterol produce eruptive xanthomas.
  • Treatment: Frequent daytime oral feedings of uncooked cornstarch (slow, continuous glucose release) and continuous nocturnal nasogastric glucose infusions. Strict avoidance of fructose and galactose (which enter metabolism upstream of G-6-P and worsen lactic acidosis).

Type II: Pompe Disease (Lysosomal Acid $\alpha$-1,4-Glucosidase Deficiency)

• Enzyme Defect: Deficiency of Lysosomal Acid Maltase (acid $\alpha$-1,4-glucosidase), which degrades 1-3% of cellular glycogen within lysosomes.
• Pathophysiology: Glycogen cannot be broken down in lysosomes, engorging lysosomal vacuoles in cardiac, skeletal, and smooth muscle fibers.
• Clinical Presentation: Infantile onset with massive cardiomegaly, hypertrophic cardiomyopathy, generalized hypotonia ("floppy baby"), severe macroglossia, hepatomegaly secondary to congestive heart failure, and early death from cardiorespiratory collapse before age 2. (Mnemonic: "Pompe trashes the Pump [heart]").

Type III: Cori Disease (Debranching Enzyme Deficiency)

• Enzyme Defect: Deficiency of $\alpha$-1,6-Glucosidase / 4-$\alpha$-glucanotransferase.
• Pathophysiology: Glycogen phosphorylase degrades glycogen normally until it reaches the branch points, where breakdown arrests. Tissues accumulate abnormal glycogen with stunted, stubby outer branches termed limit dextrins.
• Clinical Differential vs. Von Gierke: Milder clinical presentation. While patients present with hepatomegaly and mild fasting hypoglycemia, blood lactate levels are completely normal because gluconeogenesis remains 100% intact!

Type V: McArdle Disease (Skeletal Muscle Glycogen Phosphorylase Deficiency)

• Enzyme Defect: Deficiency of Myophosphorylase (muscle isoform of glycogen phosphorylase; hepatic isoform is completely normal).
• Pathophysiology: Skeletal muscle fibers cannot mobilize glycogen to generate G-1-P for anaerobic glycolysis during intense exertion. Muscle cells undergo rapid ATP exhaustion.
• Clinical Hallmarks in Podiatry & Sports Medicine:
  • Presents in young adults and athletes with severe, painful muscle cramping, fatigue, and stiffness during strenuous, short-burst exercise (such as sprinting or heavy lifting).
  • Rhabdomyolysis & Myoglobinuria: Sarcolemmal breakdown releases myoglobin into the circulation, manifesting as dark, red-brown "cola-colored" urine following exertion, predisposing to acute tubular necrosis and renal failure. Dipstick tests positive for blood, but microscopic examination demonstrates zero RBCs.
  • Zero Lactate Rise on Ischemic Forearm Test: When an ischemic forearm exercise challenge is performed, blood lactate completely fails to rise due to the block in muscle glycogenolytic substrate entry.
  • The "Second Wind" Phenomenon: After a brief rest following initial cramping, patients can resume exercise with improved tolerance. This occurs because increased local blood flow delivers blood-borne free fatty acids and hepatic glucose to the muscle, circumventing the muscle glycogen block.
  • Systemic Normoglycemia: Fasting blood glucose is entirely normal because liver glycogen phosphorylase and gluconeogenesis are intact.